Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QX-4533 in Healthy Volunteers and Moderate-to-Severe Atopic Dermatitis
NCT07800104Phase 1Recruiting
- Start
- Sep 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in atopic dermatitis (AD) comparing QX4533 with QX4533 Placebo (2 arms). Primary endpoints: Incidence of Treatment-emergent Adverse Events at Day 43 and Number of Participants with Clinically Significant Laboratory Parameter Changes at Day 43. Started Sep 2026; status: recruiting.
02
Drugs
QX-4533
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07800104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07800104.